Learning outcomes
By the end of this lesson you should be able to: define a neoplasm and explain what autonomy of growth means; apply the benign/malignant classification to a named example; derive the correct name of a benign and a malignant tumour from its tissue of origin; apply the exception rules to melanoma, lymphoma and the other names that break the pattern; and explain why a benign tumour can still be clinically dangerous.
Prerequisites
Lesson 1 (cell injury, cell division and adaptation) from this course. Neoplasia is a disorder of the cell's own growth regulation, so hypertrophy, hyperplasia and the molecular control of the cell cycle are its foundation. The pathways of angiogenesis and haemostasis from modules 1 and 2 are what malignant tumours exploit.
The big idea
Three words in that definition separate neoplasia from every other swelling. Growth exceeds the normal tissue — the question is one of relative pace, not of size. Growth is autonomous — remove the stimulus and the tumour keeps growing, unlike the hypertrophy of an exercised muscle or the hyperplasia of a wound. And the tumour is clonal — it descends from one ancestral cell whose gene expression has become abnormal and passed that abnormality on to all its descendants. Inflammation and repair swell and then settle; neoplasia does not settle.
Benign versus malignant
| Feature | Benign tumour | Malignant tumour |
|---|---|---|
| Differentiation | Resembles its tissue of origin closely | Ranges from well differentiated to undifferentiated |
| Rate of growth | Usually slow and progressive | Usually rapid, but variable — some malignant tumours exist for years |
| Mode of growth | Expansile: grows to a cohesive mass, often encapsulated | Infiltrative: invades through the basement membrane into the surrounding tissue |
| Metastasis | Does not metastasise | Metastasises to regional lymph nodes and distant organs |
| Clinical outcome | Usually curable by excision; may still be dangerous from position, hormones or haemorrhage | Progressive, drug-resistant and ultimately fatal if untreated |
| Recurrence after removal | Unusual | Common, unless the excision is wide |
Watch outBenign is not the same as harmless. A benign pituitary adenoma compresses the optic chiasm and blinds, a benign meningioma kills by pressure inside the skull, a leiomyoma of the uterus causes menorrhagia, and a benign phaeochromocytoma secretes adrenaline that kills. Malignancy is defined by invasion and metastasis, not by danger alone.
Nomenclature: derive the name from the tissue
Naming is a two-step rule, not a list to memorise. First identify the basic tissue class — epithelial or mesenchymal — then add the suffix that tells you the behaviour. Benign mesenchymal tumours take the tissue name plus -oma (lipoma, fibroma, chondroma, osteoma). Benign epithelial tumours are named by their surface pattern: papilloma when the surface is raised, adenoma when it forms glands, and cystadenoma when it forms cysts. The malignant counterparts replace -oma with -carcinoma for epithelial tumours and with -sarcoma for mesenchymal tumours.
| Tissue of origin | Benign | Malignant |
|---|---|---|
| Stratified squamous epithelium | Squamous papilloma | Squamous cell carcinoma |
| Glandular epithelium | Adenoma | Adenocarcinoma |
| Transitional epithelium | Transitional cell papilloma | Transitional cell carcinoma |
| Fat | Lipoma | Liposarcoma |
| Fibrous tissue | Fibroma | Fibrosarcoma |
| Cartilage | Chondroma | Chondrosarcoma |
| Bone | Osteoma | Osteosarcoma |
| Blood vessels | Haemangioma | Angiosarcoma |
| Lymphoid tissue | (benign reactivity only) | Lymphoma |
| Haemopoietic marrow | (does not occur) | Leukaemia |
| Melanocyte | Naevus | Melanoma |
The exceptions you must memorise
A handful of tumours break the suffix rule, and these are exactly the ones the examination asks. In every case, the exception has a historical reason and a clinical consequence: a tumour with an innocent -oma suffix that behaves malignantly.
The corollary is that some -oma tumours are malignant only in some settings: a teratoma is a benign germ cell tumour unless it is immature, and hepatoma is malignant. Mixed tumours obey the rule of their worst component: a cystosarcoma phyllodes with malignant stroma is malignant. And the two lesions that look like tumours but are not are worth separating from the concept entirely — a hamartoma is an excessive but organised growth of tissues normally present in the organ, such as the cartilage of a pulmonary hamartoma; a choristoma is a normal tissue growing at a foreign site, such as gastric mucosa in a Meckel diverticulum.
| Name | What it actually is | Why it is high-yield |
|---|---|---|
| Melanoma | Malignant tumour of melanocytes | The -oma is benign by rule but the tumour kills — an entirely metastatic disease by name |
| Lymphoma | Malignant tumour of lymphoid cells | No benign equivalent exists: lymphoid hyperplasia is not a tumour |
| Seminoma | Malignant germ cell tumour of the testis | Radiosensitive, and curability is high — name and behaviour go together |
| Hepatoma | Malignant tumour of hepatocytes | Derived from cirrhosis and hepatitis virus carriage |
| Glioma | Malignant tumour of glial cells | Grades I to IV; the most common primary brain tumour |
| Pleomorphic adenoma | Benign mixed tumour of salivary gland | Histologically mixed (epithelial and stromal) but the recurrence rate makes it a surgical problem |
Borderline and intermediate tumours
Not every tumour is a benign-or-malignant binary. Some are locally aggressive without metastasising — a desmoid-type fibromatosis invades muscle and recurs after excision but never metastasises; a cystosarcoma phyllodes is benign or malignant depending on its stromal component; a carcinoid tumour is neuroendocrine, metastasises only rarely, and may secrete hormones. Establishing that a tumour is borderline or intermediate is a real histology decision, and it is why a report on a fibromatosis or an atypical carcinoid changes management from reassurance to surveillance.
Common mistakes
Watch outSaying a lymphoma is a benign lymphoid hyperplasia. Lymphoma is a malignant tumour; the word has no benign counterpart, and its behaviour — clonal growth, infiltration, systemic spread — is the behaviour of a cancer.
Watch outCalling a melanoma benign because of the -oma ending. Melanoma is malignant; it is the reason the 'all -omas are benign' rule is taught as a rule with exceptions, not as a law of nature.
Watch outSaying a benign tumour cannot be dangerous. Position (pituitary, meninges, spinal canal), function (insulinoma, phaeochromocytoma, VIPoma) and haemorrhage (oesophageal leiomyoma) make the benign tumours clinically dangerous without any malignant behaviour.
Check your understanding
A 2 cm encapsulated mass of the thyroid is removed and called a follicular adenoma. Why is this tumour not called a carcinoma?
What does the word autonomy mean when it is said that neoplasms are autonomous?
Why is a hamartoma not considered a neoplasm?
Multiple choice
A 4 cm mass in the breast is well circumscribed and has never recurred after excision. Histology shows a fibroadenoma. What is it?
Which statement about a malignant tumour is correct?
Which of the following tumours is malignant despite its -oma suffix?
A benign phaeochromocytoma of the adrenal medulla causes fatal hypertension. Which statement best explains this?
Which feature is the most reliable criterion separating a malignant tumour from a benign one?
Summary and next
A neoplasm is an autonomous, stimulus-independent, clonal growth. It is benign when it is circumscribed and differentiated, and malignant when it invades and metastasises. Names are derived from the tissue of origin by suffix rules that every student must know and every melan memorise-exception: -oma for benign mesenchymal, adenoma/papilloma for benign epithelial, carcinoma for malignant epithelial, sarcoma for malignant mesenchymal — and melanoma, lymphoma, seminoma, hepatoma and glioma are all malignant despite the -oma.
Next: how cancers actually acquire those behaviours — the hallmarks of cancer and the gene families whose mutation makes a normal cell into a malignant one.